Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002541739 | SCV003280149 | uncertain significance | Sphingolipid activator protein 1 deficiency | 2022-08-09 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 499 of the PSAP protein (p.Pro499Ser). This variant is present in population databases (rs143773764, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with PSAP-related conditions. ClinVar contains an entry for this variant (Variation ID: 991958). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002542952 | SCV003652315 | uncertain significance | Inborn genetic diseases | 2024-11-10 | criteria provided, single submitter | clinical testing | The c.1495C>T (p.P499S) alteration is located in exon 13 (coding exon 13) of the PSAP gene. This alteration results from a C to T substitution at nucleotide position 1495, causing the proline (P) at amino acid position 499 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Natera, |
RCV001280261 | SCV001467426 | uncertain significance | Metachromatic leukodystrophy | 2020-04-11 | no assertion criteria provided | clinical testing |